EYPT vs HSIC · rev $1.2M vs P/E 24, rev $6.83B
Eyepoint Pharmaceuticals Inc (EYPT) versus Henry Schein Inc (HSIC) — a side-by-side from cached financials, not a winner call.
Eyepoint Pharmaceuticals Inc (EYPT) is a biotechnology company listed on NASDAQ.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Latest reported EYPT revenue for 2026-06-30 was $1.2M. Net income was -$179.3M. Revenue was up 72.8% from 2026-03-31 to 2026-06-30. EYPT currently screens at market cap $1.10B.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
EYPT currently screens at market cap $1.10B. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Not investment advice. Open the EYPT and HSIC stock pages for the full models.
Not investment advice.